Complete Revascularization with Multivessel PCI for Myocardial Infarction
Population Health Research Institute · Hamilton Health Sciences · +22 more institutions
Abstract
In patients with ST-segment elevation myocardial infarction (STEMI), percutaneous coronary intervention (PCI) of the culprit lesion reduces the risk of cardiovascular death or myocardial infarction. Whether PCI of nonculprit lesions further reduces the risk of such events is unclear.
We randomly assigned patients with STEMI and multivessel coronary artery disease who had undergone successful culprit-lesion PCI to a strategy of either complete revascularization with PCI of angiographically significant nonculprit lesions or no further revascularization. Randomization was stratified according to the intended timing of nonculprit-lesion PCI (either during or after the index hospitalization). The first coprimary outcome was the composite of cardiovascular death or myocardial infarction; the second coprimary outcome was the composite of cardiovascular death, myocardial infarction, or ischemia-driven revascularization.
Citation impact
- FWCI
- 95.47
- Percentile
- 100%
- References
- 25
Authors
32- SRShamir R. MehtaCorresponding
Population Health Research Institute, Hamilton Health Sciences, McMaster University
- DWDavid Wood
University of British Columbia, Population Health Research Institute
- RFRobert F. Storey
Population Health Research Institute, University of Sheffield
- RMRoxana Mehran
Hospital Universitario La Paz, Population Health Research Institute, Icahn School of Medicine at Mount Sinai
- KRKevin R. Bainey
University of Alberta, Population Health Research Institute
Topics & keywords
- Conventional PCI
- Cardiology
- Medicine
- Myocardial infarction
- Internal medicine
- Percutaneous coronary intervention
- Culprit
- Revascularization
- Good health and well-being
Funding
- ALAbbott Laboratories
- AAmgen
- BSBristol-Myers Squibb
- ELEli Lilly and Company
- PPfizer
- AAstraZeneca
- SSanofi
- CBCSL Behring
- BSBoston Scientific Corporation
- RPRegeneron Pharmaceuticals
- ACAmarin Corporation
- CMClaret Medical
- JSJanssen Scientific Affairs
- DDaiichi-Sankyo
- SServier
- IPIdorsia Pharmaceuticals
- AVAbbott Vascular
- CICanadian Institutes of Health Research
- IOInstitute of Circulatory and Respiratory Health